


## Impact on Diagnosis


Number of patients newly diagnosed with prostate cancer in 2020 (compared to same period in 2019)



\* There was a 54% reduction in the number of men diagnosed between April - June 2020 compared with same period in 2019


## Impact on Radical treatment received

Number of patients undergoing radical prostatectomy in 2020 (compared to same period in 2019)



\* There was a 48% reduction in the number of men undergoing prostatectomy between April - June 2020 compared with same period in 2019

Number of patients undergoing radical radiotherapy in 2020 (compared to same period in 2019)



\* There was a 45% reduction in the number of men undergoing radiotherapy between April - June 2020 compared with same period in 2019

## Impact on systemic therapy

Rapid and marked **fall of Docetaxel use** from April 2020 in metastatic hormone-sensitive prostate cancer. Conversely, rapid and marked **increased use of Enzalutamide**

